News
Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge Itolizumab achieved a clinical remission rate of 23.3% in ulcerative colitis patients. GuruFocus.com ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback